Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation

Peritoneal Dialysis International

Volumn 25, Issue 4, 2005, Pages 394-404

  Bazargani, Farhan ^a   Albrektsson, Ann ^a   Yahyapour, Noushin ^a   Braide, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

C5a; Coagulation; Complement; Heparin; Thrombin

Indexed keywords

COMPLEMENT COMPONENT C3A; GLUCOSE; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN ANTITHROMBIN COMPLEX; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASOPHIL; BLOOD CLOTTING; CHEMOTAXIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; EOSINOPHIL; INDWELLING CATHETER; INHIBITION KINETICS; MALE; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; ULTRAFILTRATION;

EID: 23744501974     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500416     Document Type: Article

References (46)

1. Combet S, Miyata T, Moulin P, Pouthier D, Goffin E, Devuyst O. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol 2000; 11:717-28.
2. Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993; 23(Suppl 1):141-9.
3. Jonasson P, Braide M. Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages. Perit Dial Int 1998; 18:376-81.
4. Wang T, Heimburger O, Qureshi AR, Waniewski J, Bergstrom J, Lindholm B. Physiological saline is not a biocompatible peritoneal dialysis solution. Int J Artif Organs 1999; 22(2):88-93.
5. Breborowicz A, Wieczorowska K, Martis L, Oreopoulos DG. GLycosaminoglycan chondroitin sulphate prevents loss of ultrafiltration during peritoneal dialysis in rats. Nephron 1994; 67:346-50.
6. Wieczorowska-Tobis K, Polubinska A, Breborowicz A, Oreopoulos DG. A comparison of the biocompatibility of phosphate-buffered saline and Dianeal 3.86% in the rat model of peritoneal dialysis. Adv Perit Dial 2001; 17:42-6.
7. Hekking LH, Aalders MC, Van Gelderop E, Zweers MM, Struijk DG, Havenith CE, et al. Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis. Adv Perit Dial 1998; 14:14-18.
8. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 2001; 21(Suppl 3):S368-72.
9. Styszynski A, Podkowka R, Wieczorowska-Tobis K, Kwiatkowska B, Ksiazek K, Breborowicz A, et al. Glucose suppresses peritoneal inflammatory reactions and mesothelial hyperplasia caused by intraperitoneal saline infusion. Adv Perit Dial 2002; 18:21-5.
10. Reddingius RE, Schroder CH, Daha MR, Willems HL, Koster AM, Monnens LA. Complement in serum and dialysate in children on continuous ambulatory peritoneal dialysis. Perit Dial Int 1995; 15:49-53.
11. Young GA, Kendall S, Brownjohn AM. Complement activation during CAPD. Nephrol Dial Transplant 1993; 8:1372-5.
12. Sims PJ, Wiedmer T. Induction of cellular procoagulant activity by the membrane attack complex of complement. Semin Cell Biol 1995; 6:275-82.
13. Homma S, Masunaga Y, Kurosu M, Inoue M, Sakurai T, Asano Y. Changes in peritoneal coagulation and fibrinolysis after discontinuation of chronic peritoneal dialysis. Perit Dial Int 2002; 22:178-83.
14. Cirino G, Cicala C, Bucci M, Sorrentino L, Ambrosini G, DeDominicis G, et al. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest 1997; 99: 2446-51.
15. Papapetropoulos A, Piccardoni P, Cirino G, Bucci M, Sorrentino R, Cicala C, et al. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A 1998; 95: 4738-42.
16. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Thrombin. Int J Biochem Cell Biol 1998; 30:641-6.
17. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 2002; 99:1053-9.
18. Mandl-Weber S, Cohen CD, Haslinger B, Kretzler M, Sitter T. Vascular endothelial growth factor production and regulation in human peritoneal mesothelial cells. Kidney Int 2002; 61:570-8.
19. Sarker KP, Yamahata H, Nakata M, Arisato T, Nakajima T, Kitajima I, et al. Recombinant thrombomodulin inhibits thrombin-induced vascular endothelial growth factor production in neuronal cells. Haemostasis 1999; 29:343-52.
20. Fracasso A, Baggio B, Ossi E, Del Prete D, Bonfante L, Bazzato G, et al. Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis 1999; 33:105-10.
21. Suyama K, Kumano K, Sasaki T. [Agents preventing decrease in ultrafiltration in a rat model with peritoneal hyperpermeability]. [in Japanese] Nippon Jinzo Gakkai Shi 1995; 37(9):491-6.
22. Pawlaczyk K, Kuzlan-Pawlaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16:669-71.
23. Bazzato G, Fracasso A, Gambaro G, Baggio B. Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis. Lancet 1995; 346(8977): 740-1.
24. Fracasso A, Baggio B, Masiero M, Bonfante L, Bazzato G, Feriani M, et al. Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit Dial Int 2003; 23:595-9.
25. Sjoland JA, Smith Pedersen R, Jespersen J, Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:1264-8.
26. Norrby K, Ostergaard P. A 5.0-kD heparin fraction systemically suppresses VEGF165-mediated angiogenesis. Int J Microcirc Clin Exp 1997; 17:314-21.
27. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984; 52:134-7.
28. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997; 11:51-9.
29. Jones KP, Edwards JH, Reynolds SP, Peters TJ, Davies BH. A comparison of albumin and urea as reference markers in bronchoalveolar lavage fluid from patients with interstitial lung disease. Eur Respir J 1990; 3:152-6.
30. Gillen CM, Takamata A, Mack GW, Nadel ER. Measurement of plasma volume in rats with use of fluorescent-labeled albumin molecules. J Appl Physiol 1994; 76:485-9.
31. Cui L, Carney DF, Hugli TE. Primary structure and functional characterization of rat C5a: an anaphylatoxin with unusually high potency. Protein Sci 1994; 3:1169-77.
32. Braide M, Bjursten LM. Optimized density gradient separation of leukocyte fractions from whole blood by adjustment of osmolarity. J Immunol Methods 1986; 93:183-91.
33. Holmes CJ, Lewis SL, Evans RC, Kubey WY, Luneburg P, Mucha D. Periodic elevation of complement activation products in peritoneal dialysis effluent. ASAIO Trans 1989; 35:587-9.
34. Jonasson P. Biological Effects of Glucose Degradation Products in Peritoneal Dialysis Fluids [Thesis]. Göteborg: Göteborg University; 2004.
35. Dickneite G, Czech J, Keuper H. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin. Circ Shock 1994; 42:183-9.
36. Peng WX, Guo QY, Liu SM, Liu CZ, Lindholm B, Wang T. Comparison of three chronic dialysis models. Adv Perit Dial 2000; 16:51-4.
37. Caldwell EE, Andreasen AM, Blietz MA, Serrahn JN, Vander Noot V, Park Y, et al. Heparin binding and augmentation of C1 inhibitor activity. Arch Biochem Biophys 1999; 361: 215-22.
38. Calabrese GC, Leocatanieto F, Recondo EF, Fernandez de Recondo ME. An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement system. Cell Mol Biol (Noisy-legrand) 2001; 47 Online Pub:OL119-23.
39. Park JL, Tanhehco EJ, Kilgore KS, Gralinski MR, Lucchesi BR. Reviparin-sodium prevents complement-mediated myocardial injury in the isolated rabbit heart. J Cardiovasc Pharmacol 1997; 30:658-66.
40. Gikakis N, Khan MM, Hiramatsu Y, Gorman JH 3rd, Hack CE, Sun L, et al. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation 1996; 94(9 Suppl):II341-6.
41. Kobayashi E, Kitano E, Kondo H, Kitamura H. [Complement activation in heparin - plasma inhibitory effect of anticoagulants on serum complement activation, 2nd report]. [in Japanese] Rinsho Byori 2000; 48:60-6.
42. Jarva H, Jokiranta TS, Hellwage J, Zipfel PF, Meri S. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999; 163:3957-62.
43. Gikakis N, Rao AK, Miyamoto S, Gorman JH 3rd, Khan MM, Anderson HL, et al. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1998; 116:1043-51.
44. Mousli M, Hugli TE, Landry Y, Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J Immunol 1992; 148:2456-61.
45. Dugina TN, Kiseleva EV, Glusa E, Strukova SM. Activation of mast cells induced by agonists of proteinase-activated receptors under normal conditions and during acute inflammation in rats. Eur J Pharmacol 2003; 471:141-7.
46. Rosengren BI, Rippe B. Blood flow limitation in vivo of small solute transfer during peritoneal dialysis in rats. J Am Soc Nephrol 2003; 14:1599-604.